Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.

Direct cardiovascular effects of glucagon like peptide-1

Open access
Sheikh, Asfandyar · 2013 · Diabetology & Metabolic Syndrome

Abstract

Current gold standard therapeutic strategies for T2DM target insulin resistance or β cell dysfunction as their core mechanisms of action. However, the use of traditional anti-diabetic drugs, in most cases, does not significantly reduce macrovascular morbidity and mortality. Among emerging anti-diabetic candidates, glucagon like peptide-1 (GLP-1) based therapies carry special cardiovascular implications, exerting both direct as well as indirect effects. The direct cardiovascular effects of GLP-1 and its analogs remain the focus of this review.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1758-5996-5-47

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cardiometabolic actions of GLP-1 and GLP-1 agonists [7].
Figure 1 Cardiometabolic actions of GLP-1 and GLP-1 agonists [7].CC BY · PubMed Central
Figure 2 Mechanism of action of GLP-1 [25].
Figure 2 Mechanism of action of GLP-1 [25].CC BY · PubMed Central
Figure 3 Cardiovascular effects of DPP-4 inhibitors [27].
Figure 3 Cardiovascular effects of DPP-4 inhibitors [27].CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 145 references

Cited by

See all 47

Metadata

Authors
Sheikh, A.
Affiliations
Dow University of Health Sciences (PK)
Corresponding author
Sheikh, Asfandyar
Venue
Diabetology & Metabolic Syndrome
Published
2013-08-29
Volume
5
Issue
1
Pages
47-47
ISSN
1758-5996 (ISSN-L)
OpenAlex
W2120864714
Cited by
45
References
145
Citations by year
2026: 4 · 2025: 2 · 2024: 5 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 1 · 2018: 1 · 2017: 7 · 2016: 7 · 2015: 2 · 2014: 3
FWCI
3.42
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/2.0 (tdm)
Locations
  • Diabetology & Metabolic Syndrome (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Greater South Information System
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
glucagon-like peptide-1, GLP-1 receptor agonists, cardiovascular effects, type 2 diabetes, macrovascular complications, insulin resistance, beta-cell dysfunction, antidiabetic drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Direct cardiovascular effects of glucagon like peptide-1. https://app.cochat.ai/papers/10.1186/1758-5996-5-47
The paper
Sheikh, A. (2013). Direct cardiovascular effects of glucagon like peptide-1. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/1758-5996-5-47

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.